

Early Clinical outcome of Modified retropubic Versus Transvesical prostatectomy in Management of Benign prostatic hyperplasia: a Randomised Clinical Trial

Submission date 20/08/2007	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 10/07/2008	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 11/07/2008	Condition category Urological and Genital Diseases	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Masaba Joseph Benon

Contact details

Department of Surgery

Mulago Hospital

Po Box 7051

Kampala

Uganda

256

+256 77536089

jmasaba@gmail.com

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

001

Study information

Scientific Title

Acronym

ECMVTMB: RCT

Study objectives

There is no clinical advantage of modified retropubic prostatectomy over transvesical prostatectomy.

Ethics approval required

Old ethics approval format

Ethics approval(s)

1. Research and Ethics Committee of the Faculty of Medicine, Makerere University. Date of approval: 30/07/2007
2. The Mulago National Referral Hospital Research and Ethics Committee. Date of approval: 30/07/2007

Study design

Non-blinded, randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Benign prostatic hyperplasia

Interventions

1. Modified retropubic prostatectomy
2. Transvesical prostatectomy

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Blood loss determined by haemoglobin and haematocrit levels on the third post operative day

Secondary outcome measures

1. Wound sepsis following surgery
2. Rate of return to operating theatre for clot retention

Overall study start date

01/08/2007

Completion date

28/02/2008

Eligibility**Key inclusion criteria**

1. Patients admitted between August 2007 and March 2008 with diagnosis of Benign Prostatic Hyperplasia (BPH)
2. Haemoglobin level of 10 g/dL or more
3. Haematocrit of more than 30%

Participant type(s)

Patient

Age group

Not Specified

Sex

Both

Target number of participants

68

Key exclusion criteria

1. Suspected prostatic carcinoma
2. Renal failure
3. Cardiac disease
4. Abnormal bleeding tendencies

Date of first enrolment

01/08/2007

Date of final enrolment

28/02/2008

Locations

Countries of recruitment

Uganda

Study participating centre

Department of Surgery

Kampala

Uganda

256

Sponsor information

Organisation

Mulago Hospital (Uganda)

Sponsor details

Po Box 7051

Kampala

Uganda

256

-

Sponsor type

Hospital/treatment centre

ROR

<https://ror.org/02rhp5f96>

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

Mulago Hospital (Uganda)

Funder Name

Resources of Investigator as part of Masters' thesis in surgery

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration